✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Oteracil is an investigational drug.
There have been 83 clinical trials for Oteracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.
The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Ono Pharmaceutical Co. Ltd.
There are four hundred and thirty-four US patents protecting this investigational drug and four international patents.
Recent Clinical Trials for Oteracil
|Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer||Tianjin Medical University Cancer Institute and Hospital||Phase 2|
|Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer||Anhui Chest Hospital||Phase 2|
|A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With Previously Untreated HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cance||Second Hospital of Lanzhou University||Phase 2|
Top disease conditions for Oteracil
Top clinical trial sponsors for Oteracil
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Oteracil||See Plans and Pricing||Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)||BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)||See Plans and Pricing|
|Oteracil||See Plans and Pricing||Aryl-cyanoguanidine compounds||Bayer Pharma Aktiengesellschaft (Berlin, DE)||See Plans and Pricing|
|Oteracil||See Plans and Pricing||Metal-salen complex compound, local anesthetic and antineoplastic drug||IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP)||See Plans and Pricing|
|Oteracil||See Plans and Pricing||Multimodal silica-based nanoparticles||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Oteracil||Argentina||AR098961||2033-12-23||See Plans and Pricing|
|Oteracil||Australia||AU2014372833||2033-12-23||See Plans and Pricing|
|Oteracil||Brazil||BR112016014830||2033-12-23||See Plans and Pricing|
|Oteracil||Canada||CA2934617||2033-12-23||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|